Abstract
Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2708-2712 |
| Number of pages | 5 |
| Journal | Journal of Clinical Oncology |
| Volume | 21 |
| Issue number | 14 |
| DOIs | |
| Publication status | Published - Jul 15 2003 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
HER-2 expression and cell proliferation : Prognostic markers in patients with node-negative breast cancer. / Volpi, Annalisa; Nanni, Oriana; De Paola, Franca; Granato, Anna Maria; Mangia, Annita; Monti, Franco; Schittulli, Francesco; De Lena, Mario; Scarpi, Emanuela; Rosetti, Paola; Monti, Manlio; Gianni, Lorenzo; Amadori, Dino; Paradiso, Angela.
In: Journal of Clinical Oncology, Vol. 21, No. 14, 15.07.2003, p. 2708-2712.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HER-2 expression and cell proliferation
T2 - Prognostic markers in patients with node-negative breast cancer
AU - Volpi, Annalisa
AU - Nanni, Oriana
AU - De Paola, Franca
AU - Granato, Anna Maria
AU - Mangia, Annita
AU - Monti, Franco
AU - Schittulli, Francesco
AU - De Lena, Mario
AU - Scarpi, Emanuela
AU - Rosetti, Paola
AU - Monti, Manlio
AU - Gianni, Lorenzo
AU - Amadori, Dino
AU - Paradiso, Angela
PY - 2003/7/15
Y1 - 2003/7/15
N2 - Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.
AB - Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.
UR - http://www.scopus.com/inward/record.url?scp=0041629495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041629495&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.04.008
DO - 10.1200/JCO.2003.04.008
M3 - Article
C2 - 12860948
AN - SCOPUS:0041629495
VL - 21
SP - 2708
EP - 2712
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 14
ER -